Literature DB >> 3500409

Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City.

R Rothenberg1, M Woelfel, R Stoneburner, J Milberg, R Parker, B Truman.   

Abstract

In a cohort of 5833 subjects in whom the acquired immunodeficiency syndrome (AIDS) was diagnosed in New York City before 1986, the cumulative probability of survival (mean +/- SE) was 48.8 +/- 0.7 percent at one year and 15.2 +/- 1.8 percent at five years. The group with the most favorable survival rate--white homosexual men 30 to 34 years old who presented with Kaposi's sarcoma only--had a one-year cumulative probability of survival of 80.5 percent; that group was used as the reference group in assessing the effect of five variables: sex, race or ethnic background, age, probable route of acquiring AIDS (risk group), and manifestations of AIDS at diagnosis. The range in the mortality rate was greater than threefold, depending on these variables. Black women who acquired the disease through intravenous drug abuse, for example, had a particularly poor prognosis. The manifestations of disease at diagnosis had the most influence on survival, accounting on average for 56.3 percent of the excess risk. This variable was followed in importance by age (12.2 percent), race or ethnicity (10.6 percent), risk group (8.4 percent), and sex (8.0 percent), with 4.5 percent of the risk attributable to interactions between variables. When we compared subcohorts based on the year of diagnosis (1981 through 1985), we found a significant improvement in the one-year cumulative probability of survival among subjects with Pneumocystis carinii pneumonia, but not among subjects without P. carinii pneumonia.

Entities:  

Mesh:

Year:  1987        PMID: 3500409     DOI: 10.1056/NEJM198711193172101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  67 in total

1.  Demographic characteristics and survival with AIDS: health disparities in Chicago, 1993-2001.

Authors:  Girma Woldemichael; Demian Christiansen; Sandra Thomas; Nanette Benbow
Journal:  Am J Public Health       Date:  2009-02-12       Impact factor: 9.308

2.  Bleach programs for preventing AIDS among i.v. drug users: modeling the impact of HIV prevalence.

Authors:  J E Siegel; M C Weinstein; H V Fineberg
Journal:  Am J Public Health       Date:  1991-10       Impact factor: 9.308

3.  Efficacy of intravenous immunoglobulins in patients with advanced HIV-1 infection. A randomized clinical study.

Authors:  U Brunkhorst; M Stürner; H Willers; H Deicher; I Schedel
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

4.  Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS).

Authors:  G R Seage; S Landers; G A Lamb; A M Epstein
Journal:  Am J Public Health       Date:  1990-07       Impact factor: 9.308

5.  HIV positive patients first presenting with an AIDS defining illness: characteristics and survival.

Authors:  M C Poznansky; R Coker; C Skinner; A Hill; S Bailey; L Whitaker; A Renton; J Weber
Journal:  BMJ       Date:  1995-07-15

6.  Patterns of survival with AIDS in the United States.

Authors:  J Piette; V Mor; J Fleishman
Journal:  Health Serv Res       Date:  1991-04       Impact factor: 3.402

7.  Sex disparities in outcomes among adults on long-term antiretroviral treatment in northern Nigeria.

Authors:  Baba M Musa; Musa A Garbati; Ibrahim M Nashabaru; Shehu M Yusuf; Aisha M Nalado; Daiyabu A Ibrahim; Melynda N Simmons; Muktar H Aliyu
Journal:  Int Health       Date:  2016-12-09       Impact factor: 2.473

Review 8.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 9.  Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms.

Authors:  Victor G Valcour; Cecilia M Shikuma; Michael R Watters; Ned C Sacktor
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

Review 10.  The same but different: autologous hematopoietic stem cell transplantation for patients with lymphoma and HIV infection.

Authors:  R F Ambinder
Journal:  Bone Marrow Transplant       Date:  2009-05-18       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.